الفهرس | Only 14 pages are availabe for public view |
Abstract Chronic kidney disease is(CKD)is a major public health problem. Early diagnosis and treatment are important to arrest the progression and prevent complications.Most CKD biomarkers currently in clinical use are not sensitive enough and cannot be used to identify early stage of the disease. CKD is defined as either kidney damage or decreased kidney function(decreased GFR)for 3 or more months.The klotho gene was discovered in 1997 as a gene whose expression was defective in a mouse strain showing complex phenotypes resembling human aging. Klotho is a nephroprotective transmembrane protein predominantly expressed in the renal tubules and implicated in regulating phosphate metabolism, together with fibroblast growth factor-23(FGF-23). FGF-23, a bone-derived hormone secreted in response to dietary phosphate intake, acts in the kidneys, increasing urinary phosphate excretion in α-klotho-dependent manner to maintain healthy phosphorus homeostasis.The aim of this work was to study soluble serum α-klotho in different stages of CKD in relative to kidney function and mineral metabolism derangement to throw more light on its clinical significance in CKD. The present study was carried out on 50 patients referred to Internal Medicine Hospital of Tanta University and 30 apparently healthy individuals of matched age and sex as a control group. |